Istaroxime, a potential anticancer drug in prostate cancer, exerts beneficial functional effects in healthy and diseased human myocardium

The current gold standard for prostate cancer treatment is androgen deprivation therapy and antiandrogenic agents. However, adverse cardiovascular events including heart failure can limit therapeutic use. Istaroxime, which combines Na(+)-K(+)-ATPase (NKA) inhibition with sarco/endoplasmic reticulum...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallner, Markus, Khafaga, Mounir, Kolesnik, Ewald, Vafiadis, Aris, Schwantzer, Gerold, Eaton, Deborah M., Curcic, Pero, Köstenberger, Martin, Knez, Igor, Rainer, Peter P., Pichler, Martin, Pieske, Burkert, Von Lewinski, Dirk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564766/
https://www.ncbi.nlm.nih.gov/pubmed/28514771
http://dx.doi.org/10.18632/oncotarget.17540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5564766/
https://www.ncbi.nlm.nih.gov/pubmed/28514771
http://dx.doi.org/10.18632/oncotarget.17540

Ejemplares similares